After co‐encapsulating SLO‐Gal and SLO‐NEU in hyaluronic acid (HA) cross‐linked shell, the constructed TEID can be specifically recognized by a cluster of differentiation 44 (CD44) on the tumor cell surface to achieve targeted delivery and HAase‐mediated degradation in the tumor microenvironment,[18] which releases SLO‐Gal and SLO‐NEU to anchor the NEU and Gal on cell membrane via perforation. The gene discussed is CD44; the disease is neoplasm.